SNYDER CAPITAL MANAGEMENT L P - HALOZYME THERAPEUTICS INC ownership

HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 231 filers reported holding HALOZYME THERAPEUTICS INC in Q4 2019. The put-call ratio across all filers is 0.38 and the average weighting 0.2%.

Quarter-by-quarter ownership
SNYDER CAPITAL MANAGEMENT L P ownership history of HALOZYME THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$165,185,662
+5.9%
4,324,232
+0.0%
3.73%
+12.3%
Q2 2023$155,949,078
-4.9%
4,323,512
+0.7%
3.32%
-5.0%
Q1 2023$164,033,077
-27.6%
4,295,184
+7.8%
3.50%
-31.7%
Q4 2022$226,679,017
+29.7%
3,983,814
-9.8%
5.12%
+14.5%
Q3 2022$174,724,000
-3.4%
4,418,928
+7.5%
4.47%
-8.8%
Q2 2022$180,848,000
+12.2%
4,110,174
+1.7%
4.90%
+19.3%
Q1 2022$161,231,000
-1.4%
4,042,906
-0.5%
4.10%
+4.0%
Q4 2021$163,445,000
+17.2%
4,064,779
+18.6%
3.95%
+6.9%
Q3 2021$139,430,000
-3.3%
3,427,476
+7.9%
3.69%
-8.5%
Q2 2021$144,241,000
+18.5%
3,176,404
+8.7%
4.04%
+15.3%
Q1 2021$121,771,000
-13.6%
2,920,860
-11.5%
3.50%
-24.1%
Q4 2020$140,943,000
+58.7%
3,300,001
-2.4%
4.61%
+21.2%
Q3 2020$88,824,000
-2.6%
3,379,927
-0.6%
3.81%
-7.8%
Q2 2020$91,193,000
+49.4%
3,401,470
+0.2%
4.13%
+18.8%
Q1 2020$61,041,000
-1.5%
3,393,057
-2.9%
3.48%
+42.5%
Q4 2019$61,982,000
+46.8%
3,495,892
+28.4%
2.44%
+31.7%
Q3 2019$42,216,000
-10.0%
2,721,858
-0.3%
1.85%
-11.9%
Q2 2019$46,884,000
+3.0%
2,729,005
-3.5%
2.10%
-2.1%
Q1 2019$45,508,000
+9.8%
2,826,601
-0.3%
2.15%
-4.3%
Q4 2018$41,458,000
-4.4%
2,833,759
+18.7%
2.24%
+16.3%
Q3 2018$43,378,000
+8.2%
2,387,350
+0.5%
1.93%
+1.6%
Q2 2018$40,081,000
-13.0%
2,375,876
+1.0%
1.90%
-16.7%
Q1 2018$46,086,000
-3.9%
2,352,525
-0.6%
2.28%
-4.7%
Q4 2017$47,945,000
+11.9%
2,366,480
-4.1%
2.39%
+11.5%
Q3 2017$42,846,000
+32.2%
2,466,684
-2.4%
2.14%
+24.7%
Q2 2017$32,415,000
+7.9%
2,528,462
+9.1%
1.72%
+8.3%
Q1 2017$30,047,000
+41.8%
2,318,433
+8.1%
1.58%
+23.2%
Q4 2016$21,188,000
-21.4%
2,144,549
-3.9%
1.29%
-23.8%
Q3 2016$26,964,000
+37.8%
2,232,114
-1.6%
1.69%
+32.6%
Q2 2016$19,571,000
+23.0%
2,267,787
+35.0%
1.27%
+18.1%
Q1 2016$15,911,0001,680,1691.08%
Other shareholders
HALOZYME THERAPEUTICS INC shareholders Q4 2019
NameSharesValueWeighting ↓
Third Security, LLC 1,129,551$47,091,0006.38%
First Light Asset Management, LLC 2,011,350$83,853,0005.56%
TRAN CAPITAL MANAGEMENT, L.P. 1,353,208$56,415,0005.03%
SNYDER CAPITAL MANAGEMENT L P 2,920,860$121,771,0003.50%
DOHENY ASSET MANAGEMENT /CA 120,028$5,004,0003.39%
SILVERARC CAPITAL MANAGEMENT, LLC 104,945$4,375,0002.39%
Redwood Investments, LLC 542,764$22,628,0001.99%
Kent Lake Capital LLC 85,000$3,544,0001.44%
Lisanti Capital Growth, LLC 263,460$10,984,0001.41%
Bellevue Group AG 3,011,966$125,569,0001.33%
View complete list of HALOZYME THERAPEUTICS INC shareholders